Biogen subpoenaed by federal government over MS drug prices
Biogen disclosed Thursday that it received a subpoena late last year from federal investigators related to the price of its top multiple sclerosis drugs, including blockbuster treatment Tecfidera.
Cambridge-based Biogen (Nasdaq: BIIB) said in its annual federal filing that it had received a subpoena on Dec. 5 seeking information regarding "government price reporting, rebate payments and Biogen's co-pay assistance programs" for MS drugs Tecfidera, Avonex, Tysabri and Plegridy. The company sa id it… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - February 2, 2017 Category: American Health Authors: Max Stendahl Source Type: news
Biogen subpoenaed by federal government over MS drug prices
Biogen disclosed Thursday that it received a subpoena late last year from federal investigators related to the price of its top multiple sclerosis drugs, including blockbuster treatment Tecfidera.
Cambridge-based Biogen (Nasdaq: BIIB) said in its annual federal filing that it had received a subpoena on Dec. 5 seeking information regarding "government price reporting, rebate payments and Biogen's co-pay assistance programs" for MS drugs Tecfidera, Avonex, Tysabri and Plegridy. The company sa id it… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 2, 2017 Category: Biotechnology Authors: Max Stendahl Source Type: news
Rebif (Interferon beta-1a) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 25, 2017 Category: Drugs & Pharmacology Source Type: news
New drug proves effective for both types of MS
Conclusion
This study shows promising results for a new approach to treating MS. However, the study period is relatively short (96 weeks is about 20 months, so less than two years) and MS is a long-term disease. If this drug is approved for use, longer studies will be needed to be sure that this treatment lives up to its early promise over many years and to monitor for adverse reactions in real life, particularly cancers.
Some people with relapsing remitting MS do well on existing treatments, and have only infrequent relapses of mild symptoms which get worse very slowly.
But for most patients on standard treatment, the dam...
Source: NHS News Feed - December 22, 2016 Category: Consumer Health News Tags: Neurology Medication Source Type: news
Roche says new MS drug works better than Merck's Rebif
ZURICH (Reuters) - Roche said on Wednesday its Ocrevus multiple sclerosis drug controlled the most common form of the disease better than a rival's medicine and worked against another form of MS for which there is no approved treatment. (Source: Reuters: Health)
Source: Reuters: Health - September 14, 2016 Category: Consumer Health News Tags: healthNews Source Type: news
Avonex (interferon beta 1a injection)
Title: Avonex (interferon beta 1a injection) Category: MedicationsCreated: 3/2/2005 12:00:00 AMLast Editorial Review: 6/8/2016 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - June 8, 2016 Category: Drugs & Pharmacology Source Type: news
Ocrelizumab bests interferon for relapsing MS at 2 years
VANCOUVER – Ocrelizumab, a B-cell depleting humanized monoclonal antibody being developed by Hoffman–La Roche, consistently outperformed interferon beta-1a (Rebif) for relapsing multiple sclerosis in... (Source: Family Practice News)
Source: Family Practice News - May 25, 2016 Category: Primary Care Source Type: news
Ocrelizumab bests interferon for relapsing MS at 2 years
VANCOUVER – Ocrelizumab, a B-cell depleting humanized monoclonal antibody being developed by Hoffman–La Roche, consistently outperformed interferon beta-1a (Rebif) for relapsing multiple sclerosis in... (Source: Clinical Neurology News)
Source: Clinical Neurology News - May 25, 2016 Category: Neurology Source Type: news
Avonex (Interferon beta-1a) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 5, 2016 Category: Drugs & Pharmacology Source Type: news
Biogen reports positive data of daclizumab over interferon beta-1a im to treat multiple sclerosis
Global biotechnology company Biogen has reported new data that demonstrates daclizumab’s positive cognitive outcomes, targeted and reversible mechanism of action (MOA), and safety profile over interferon beta-1a im in relapsing-remitting multiple scl… (Source: Drug Development Technology)
Source: Drug Development Technology - May 3, 2016 Category: Pharmaceuticals Source Type: news
Merck KGaA bets on cancer drugs to revitalize German firm
TEL AVIV (Reuters) - Merck KGaA is betting on its oncology pipeline to revitalize the German drugmaker as it sees falling sales from its best-selling medicine, multiple sclerosis treatment Rebif. (Source: Reuters: Health)
Source: Reuters: Health - October 12, 2015 Category: Consumer Health News Tags: healthNews Source Type: news
Positive Topline Results for Investigational MS DrugPositive Topline Results for Investigational MS Drug
Two phase 3 studies suggest the investigational drug ocrelizumab is superior to interferon beta-1a in reducing the relapse rate in patients with relapsing multiple sclerosis. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - July 9, 2015 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Positive Topline Results for Investigational MS DrugPositive Topline Results for Investigational MS Drug
Two phase 3 studies suggest the investigational drug ocrelizumab was superior to interferon beta-1a in reducing the relapse rate in patients with relapsing multiple sclerosis. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 30, 2015 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Roche’s ocrelizumab significantly reduced both relapses and disability progression versus interferon beta-1a (Rebif®) in two Phase III studies in multiple sclerosis
Roche today announced positive results from two pivotal studies evaluating the investigational medicine ocrelizumab compared with interferon beta-1a (Rebif®), a standard-of-care therapy, in people with relapsing multiple sclerosis (MS), the most common form of the disease. (Source: Roche Investor Update)
Source: Roche Investor Update - June 30, 2015 Category: Pharmaceuticals Source Type: news
Roche’s ocrelizumab significantly reduced both relapses and disability progression versus interferon beta-1a (Rebif®) in two Phase III studies in multiple sclerosis
Roche today announced positive results from two pivotal studies evaluating the investigational medicine ocrelizumab compared with interferon beta-1a (Rebif®), a standard-of-care therapy, in people with relapsing multiple sclerosis (MS), the most common form of the disease. (Source: Roche Media News)
Source: Roche Media News - June 30, 2015 Category: Pharmaceuticals Source Type: news
